Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kusha A Mohammadi

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 22, 2022
Mediating Effects of Neighborhood-Level Socioeconomic Deprivation on the Association Between Race/Ethnicity and Advanced Hepatocellular CarcinomaAbiodun O Oluyomi, Kusha A Mohammadi, Hashem B El-Serag, et al.
Cancer Medicine|November 29, 2022
Serum cholesterol and the risk of developing hormonally driven cancers: A narrative reviewDana J Murdock, Robert J Sanchez, Kusha A Mohammadi, et al.
Cancer Medicine|July 17, 2023
Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trialsKusha A Mohammadi, Taylor Brackin, Gregory G Schwartz, et al.
American Journal of Preventive Cardiology|December 17, 2024
Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMESGregory P Geba, Ruifeng Chen, Kasturi Talapatra, et al.
Scientific Reports|August 7, 2023
Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profilesDateng Li, Meng Xu, Andrea T Hooper, et al.
Journal of the American Heart Association|August 23, 2025
Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES TrialGregory P Geba, Kusha A Mohammadi, Amy Damask, et al.
Lancet (London, England)|November 11, 2025
Efficacy and safety of REGN9933<sup>A2</sup> and REGN7508<sup>Cat</sup> for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trialsJeffrey I Weitz, Aaron P Kithcart, Meagan P O'Brien, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 22, 2022
Mediating Effects of Neighborhood-Level Socioeconomic Deprivation on the Association Between Race/Ethnicity and Advanced Hepatocellular CarcinomaAbiodun O Oluyomi, Kusha A Mohammadi, Hashem B El-Serag, et al.
Cancer Medicine|November 29, 2022
Serum cholesterol and the risk of developing hormonally driven cancers: A narrative reviewDana J Murdock, Robert J Sanchez, Kusha A Mohammadi, et al.
Cancer Medicine|July 17, 2023
Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trialsKusha A Mohammadi, Taylor Brackin, Gregory G Schwartz, et al.
American Journal of Preventive Cardiology|December 17, 2024
Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMESGregory P Geba, Ruifeng Chen, Kasturi Talapatra, et al.
Scientific Reports|August 7, 2023
Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profilesDateng Li, Meng Xu, Andrea T Hooper, et al.
Journal of the American Heart Association|August 23, 2025
Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES TrialGregory P Geba, Kusha A Mohammadi, Amy Damask, et al.
Lancet (London, England)|November 11, 2025
Efficacy and safety of REGN9933<sup>A2</sup> and REGN7508<sup>Cat</sup> for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trialsJeffrey I Weitz, Aaron P Kithcart, Meagan P O'Brien, et al.
Pageof 1